Journal of Public Health Policy

, Volume 29, Issue 1, pp 106–120 | Cite as

Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia

Article

Abstract

This paper outlines the increasing salience of drug “innovation” in the debate for reform of Australia's pharmaceutical policy, particularly change to Australia's price control mechanisms. The pharmaceutical industry has consistently criticised the central role of price control in Australia's pharmaceutical regulatory regime as an impediment to drug innovation and industry growth. Despite ambivalent or contrary evidence on the impact of price control on drug innovation, this criticism, and the appeals for reform it supports, appear to be increasingly influential in directing pharmaceutical policy. This is particularly evident in the implementation of the Australia/United States Free Trade Agreement, which has led to a weakening of the historical process of evidence-based reference pricing in Australia. Should drug innovation come to dominate Australian pharmaceutical policy, there is the potential to precipitate a devaluing of the current public orientation of regulation and diminish equitable access to affordable pharmaceuticals. The manner in which trade policy has effectively undermined a publicly funded pharmaceutical benefits scheme has clear implications for many countries that maintain such programmes.

Keywords

price control innovation pharmaceutical policy equity 

References

  1. Sell S . The quest for global governance in intellectual property and public health: structural, discursive and institutional dimensions. Paper Prepared for International Studies Association Conference Montreal, Canada, 17–20 March 2004. Available at http://cyber.law.harvard.edu/blogs/gems/politicshiv/sell.pdf, last accessed 14 April 2007.
  2. Sweeney K . Review of findings: Australian pharmaceutical pricing in the global context. Working Paper No. 19 (Final) Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2004. Available at http://www.cfses.com, last accessed 14 April 2007.
  3. Faunce T, Doran E, Henry D, Drahos P, Searles A, Pekarsky B, et al. Assessing the impact of the Australia–United States Free Trade Agreement on Australian and global medicines policy. Globalization Health. 2005;1:15.CrossRefGoogle Scholar
  4. Salkeld G, Mitchell A, Hill S . Pharmaceuticals. In: Mooney G, Scotton R, editors. Economics and Australian Health Policy. Australia: Allen and Unwin; 1998, p. 115–136.Google Scholar
  5. Hassett KA . Price Controls and the Evolution of Pharmaceutical Markets Draft Paper American Enterprise Institute 2004. Available at https://www.who.int/intellectualproperty/news/en/Submission-Hassett.pdf, accessed 16 October 2006.
  6. Lofgren H, De Boer R . Pharmaceuticals in Australia: developments in regulation and governance. Soc Sci Med. 2004;58:2397–2407.CrossRefGoogle Scholar
  7. Productivity Commission. International pharmaceutical price differences. Research Report. Ausinfo, Canberra. Available at http://www.pc.gov.au/study/pbsprices/finalreport/index.html, 2001.
  8. Productivity Commission. Evaluation of the pharmaceutical industry investment program. Research Report. Ausinfo, Canberra. Available at http://www.pc.gov.au/study/piip/finalreport/index.html, 2003.
  9. Dalton A . Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else. Austral Health Rev. 2001;24 (2):7–14.CrossRefGoogle Scholar
  10. Richardson J . Priorities of health policy: cost shifting or population health. Working Paper 147. Centre for Health Economics, Monash University, Melbourne 2004. Available at http://www.buseco.monash.edu.au/centres/che/pubs/wp147.PDF.
  11. Harvey K, Murray M . Medicinal drug policy. In: Gardner H, editor. The Politics of Health, 2nd edition. Melbourne: Churchill Livingstone; 1995, p. 238–283.Google Scholar
  12. Davey P, Lees M, Aristides M, Ziss S . Report on the Australian System of Pharmaceutical Financing and Delivery. Efficiency and Equity Implications of Public versus Private Funding of Pharmaceuticals, vol. 1. Australia: Medical Technology Assessment Group; 1999.Google Scholar
  13. Davey P, Lees M, Aristides M . Report on the Australian system of pharmaceutical financing and delivery. Cost-effectiveness of pharmaceuticals, vol. 2 Australia: Medical Technology Assessment Group; 1999.Google Scholar
  14. Productivity Commission. Impact of advances in medical technology on Australia. Research Report. Melbourne. Available at http://www.pc.gov.au/study/medicaltechnology/finalreport/medicaltechnology.pdf, 2005.
  15. Calfee JE . Prices, Markets and the Pharmaceutical Revolution. AEI: Washington DC; 2000.Google Scholar
  16. Danzon PM . Pharmaceutical Price Regulation; National Policies versus Global Interests. Washington, DC: American Enterprise Institute; 1997.Google Scholar
  17. Kemp R . Australia's ‘free-ride’ in pharmaceuticals: can it last? Austral Health Rev. 1996;19:81–93.CrossRefGoogle Scholar
  18. Sheehan P . Pharmaceuticals and public policy: an assessment of the Productivity Commission Draft Report. A submission to the Productivity Commission. Centre for Strategic Economic Studies, Victoria University of Technology 2003. Available at http://www.cfses.com.
  19. Schneerman K . The pharmaceuticals industry: prescription for the health and wealth of the nation. Australian Chief Executive, July 2003: 38–40.Google Scholar
  20. Sheehan P . Pharmaceuticals, health and industry development: strategic issues and options. Pharmaceutical Industry Project Equity, Sustainability and Industry Development Working Paper Series, Working Paper No. 13. Centre for Strategic Economic Studies 2002. Available at http://www.cfses.com.
  21. Rasmussen B . Innovation and industry structure in the biomedical industry: some preliminary results. Working Paper No. 17 (Final Draft). Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2004a. Available at http://www.cfses.com.
  22. Rasmussen B . Alliance opportunities for AusBiotech. Pharmaceutical Industry Project Working Paper Series, Working Paper No. 23. Centre for Strategic Economic Studies, 2004b. Available at http://www.cfses.com.
  23. Rasmussen B . Developing the biomedical industries in Canada and Australia: an innovation systems approach. Working Paper No. 24, Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2005. Available at http://www.cfses.com.
  24. Coombs R, Metcalfe S J . Innovation in pharmaceuticals: perspectives on the co-ordination, combination and creation of capabilities. Technol Anal Strat Manage. 2002;14 (3):261–271.CrossRefGoogle Scholar
  25. McKelvey M, Orsenigo L . Pharmaceuticals as a sectoral innovation system. Paper prepared for the ESSY Project (European Sectoral Systems of Innovation) and within the Epris Project 2001. Available at http://www.druid.dk/conferences/winter2002/gallery/orsenigo.PDF.
  26. Gassmann O, Reepmeyer G . Organizing pharmaceutical innovation: from science-based knowledge creators to drug-oriented knowledge brokers. Creat Innovat Manage. 2005;14 (3):233–245.CrossRefGoogle Scholar
  27. DiMasi JA, Hansen RW, Grabowski HG . The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22 (2):151–185.CrossRefGoogle Scholar
  28. Barton JH, Emmanuel EJ . The patents-based pharmaceutical development process: rationale problems and potential reforms. JAMA. 2005;294 (16):2075–2082.CrossRefGoogle Scholar
  29. Sharma A, Lacey N . Linking product development outcomes to market valuation of the firm: the case of the U.S. pharmaceutical industry. J Prod Innovat Manage. 2004;21:297–308.CrossRefGoogle Scholar
  30. Orsenigo L, Pammolli F, Riccaboni M . Technological change and network dynamics: lessons from the pharmaceutical industry. Res Pol. 2001;30:485–508.CrossRefGoogle Scholar
  31. Pammolli F, Riccaboni M . Market structure and innovation. Health Affairs. 2004;23 (1):48–50.CrossRefGoogle Scholar
  32. Wagner JL, McCarthy E . International differences in drug prices. Annu Rev Pub Health. 2004;25:475–495.CrossRefGoogle Scholar
  33. Lacetera N, Orsenigo L . Political regimes, technological regimes and innovation in the evolution of the pharmaceutical industry in the USA and in Europe. Paper prepared for the “Conference on Evolutionary Economics”, Johns Hopkins University, Baltimore, 30–31 March 2001. Available at http://www.fgcasal.org/politicafarmaceutica/docs/Nicola_Lacetera_and_Luigi_Orsenigo.PDF.
  34. Acemoglu D, Linn J . Market size in innovation: theory and evidence from the pharmaceutical industry. Quart J Econ. August 2004;199:1049–1090.CrossRefGoogle Scholar
  35. McKelvey M, Orsenigo L . Pharmaceuticals as sectoral innovation system. Paper prepared for the ESSY Project (European Sectoral Systems of Innovation), 2001. Available at http://www.druid.dk/conferences/winter2002/gallery/orsenigo.PDF.
  36. Light DW, Lexchin J . Foreign free riders and the high price of US medicines. Br Med J. 2005;331:958–960.CrossRefGoogle Scholar
  37. Love J . Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines, 2003. Available at http://www.cptech.org/ip/health/rnd/evidenceregardingrnd.pdf.
  38. Wright DJ, Profitability and leakage under the PBS Australian Review of Public Affairs, 2003. Available at http://www.australianreview.net/digest/2003/12/wright.html.
  39. Wright DJ . The drug bargaining game: pharmaceutical regulation in Australia. J Health Econ. 2004;23 (4):785–813.CrossRefGoogle Scholar
  40. Grattan M, Stafford A . US drug companies eye Australia. The Age, 29 August 2006.Google Scholar
  41. Sutherland T . US envoy targets trade issues. The Australian Financial Review, 29 August 2006.Google Scholar
  42. Mecurio B . The impact of the Australia United States Free Trade Agreement on the provision of health services in Australia. Whittier Law Rev. 2005;26:1051.Google Scholar
  43. Haynes S . The triumph is in the text: Australia – United States Free Trade Agreement: new opportunities and impacts. Available at http://www.apec.org.au/docs/fta04Haynes.pdf.
  44. Drahos P, Lokuge B, Faunce T, Goddard M, Henry D . Pharmaceuticals, intellectual property and free trade: the case of the US–Australia free trade agreement. Prometheus. 2004;22 (3):243–257.CrossRefGoogle Scholar
  45. Lokuge B, Faunce TA . Trade disputes and the pharmaceutical benefits scheme: constructive ambiguities, non-violation nullification disputes and the Australia-United States Free Trade Agreement. Working Paper Centre for Governance of Knowledge and Development, 2004. Available at http://cgkd.anu.edu.au/menus/PDFs/TradedisputesandthePharmaceuticalBenefitsScheme.pdf.
  46. Harvey KJ, Faunce TA, Lokuge B, Drahos P . Will the Australia–United States Free Trade Agreement undermine the pharmaceutical benefits scheme? Med J Aust. 2004;181 (5):256.Google Scholar
  47. Surel Y . The role of cognitive and normative frames in policy-making. J European Pub Pol. 2000;7 (4):495–512.CrossRefGoogle Scholar
  48. Campbell JL . Ideas, politics and public policy. Annu Rev Sociol. 2002;28:21–38.CrossRefGoogle Scholar

Copyright information

© Palgrave Macmillan Ltd 2008

Authors and Affiliations

  1. 1.Clinical Pharmacology, University of Newcastle, Mater HospitalWaratahAustralia

Personalised recommendations